CD22 and neoplasm: Co-administration of CD19 and CD22 CAR-T cells can kill CD19+CD22−, CD19−CD22+, and CD19+CD22+ tumor cells, thereby avoiding tumor escape caused by heterogeneous expression of antigens [10, 34].